Sean Wuxiong Cao - 14 May 2026 Form 4 Insider Report for NovaBridge Biosciences (NBP)

Reporting relationship: Chief Business Development Officer and Director, Director
Issuer ticker: NBP
Reported as of: 14 May 2026
Net transaction value: -$42,584
SEC form: 4
Accepted by SEC: 18 May 2026, 16:05:10 UTC
Prior SEC filing: 18 Mar 2026
Next SEC filing: 24 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Xi-Yong (Sean) Fu, as attorney-in-fact

Key filing fact

Sean Wuxiong Cao filed Form 4 for NovaBridge Biosciences (NBP) on 18 May 2026.

Key facts

This page summarizes Sean Wuxiong Cao's Form 4 filing for NovaBridge Biosciences (NBP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 May 2026, 16:05.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: -$42,584.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002109966 Primary reporting owner

Cao Sean Wuxiong

Relationship: Chief Business Development Officer and Director, Director
Address: C/O NOVABRIDGE BIOSCIENCES,, 2440 RESEARCH BOULEVARD, SUITE 400, ROCKVILLE
Signature: /s/ Xi-Yong (Sean) Fu, as attorney-in-fact
Signature date: 18 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBP transaction

Ordinary Shares

Sale

Transaction value: $42,584
Shares: -21,399
Change %: -38%
Price: $1.99
Shares after: 35,073
Date: 14 May 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

Footnote F2

The reporting person sold 9,304 ADSs representing approximately 21,399 ordinary shares in connection with the partial vesting of a restricted stock unit award on January 31, 2026, solely to satisfy tax withholding obligations incurred in connection with the vesting.

Footnote F3

Price expressed in terms of ADSs.

Footnote F4

The reported securities are represented by 15,249 ADSs.

SEC remarks

Chief Business Development Officer and Director